Trial Profile
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms HOVON 126 MM
- 21 Jul 2023 This trial has been completed in Denmark (End Date: 01 May 20230, according to European Clinical Trials Database record.
- 04 Dec 2018 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Results of the final analysis of induction therapy and preliminary results of the randomization phase of the study, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology